-

08:06:13 AM

INKT Stock News

INKT - MiNK Therapeutics Inc

03/30/23 8:41 AM

Nasdaq : AGEN, INKT

dividends

Agenus Announces Dividend of 5 Million Shares of MiNK Therapeutics

Agenus Inc., an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that its Board of Directors has declared a dividend of 5 million shares of common stock of its subsidiary, MiNK Therapeutics, Inc., to shareholders of Agenus as of April 17, 2023. "We are excited to declare the distribution of...

RHEA-AI

neutral

03/21/23 8:00 AM

Nasdaq : INKT

earningslow float

MiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Clinical update of allo-iNKTs (agenT-797) in solid tumors to be presented at AACR Annual Meeting in April 2023 AgenT-797 in combination with pembro or nivo in NSCLC and gastric cancer to initiate in 2023 Allogeneic CAR platform demonstrates differentiation with IL-15-FAP-CAR-iNKT (MiNK-215) and

RHEA-AI

neutral

03/15/23 8:45 AM

Nasdaq : INKT

conferencesclinical triallow float

MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and

RHEA-AI

neutral

03/07/23 9:00 AM

Nasdaq : INKT

conferencesearningslow float

MiNK Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other

RHEA-AI

neutral

02/16/23 9:28 AM

Nasdaq : INKT

conferenceslow float

MiNK Therapeutics to Participate in HC Wainwright Cell Therapy Virtual Conference

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated

RHEA-AI

neutral

01/11/23 2:25 PM

Nasdaq : INKT

conferenceslow float

MiNK Therapeutics to Participate in B. Riley Securities Oncology Conference

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated

RHEA-AI

neutral

11/17/22 9:00 AM

Nasdaq : INKT

conferenceslow float

MiNK Therapeutics to Participate in Evercore ISI HealthCONx Conference

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated

RHEA-AI

neutral

11/10/22 9:05 AM

Nasdaq : INKT

clinical triallow float

MiNK Presents Clinical Data at SITC 2022 Showcasing iNKT Cell Therapy Pipeline

Allogeneic off-the-shelf iNKT cell therapy, agenT-797, alone and in combination with pembro/nivo reports early clinical activity in solid tumors, with 27% and 66% of patients, respectively, had a reduction of target and non-target lesions or disease stabilization First immune cell therapy

RHEA-AI

neutral

11/03/22 8:00 AM

Nasdaq : INKT

earningslow float

MiNK Therapeutics Reports Corporate Update and Third Quarter 2022 Financial Results

MiNK Therapeutics, Inc., a clinical-stage

RHEA-AI

neutral

10/20/22 9:00 AM

Nasdaq : INKT

conferencesearningslow float

MiNK Therapeutics to Report Third Quarter 2022 Financial Results and Business Update

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T

RHEA-AI

neutral